Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT01568567

Study to Demonstrate the Safety of a Novel Powder Formulation of Lactobacilli in Adults (BSSII)

To Demonstrate That a Novel Powder Formulation of Lactobacillus Reuteri DSM 17938 is Safe in Adults, a Randomized, Placebo Controlled Double-blind Study

Sponsor: BioGaia AB

Conditions Safety

Interventions Lactobacillus Reuteri DSM 17938

Updated 5 times since 2017 Last updated: Jul 3, 2012 Started: Mar 31, 2012 Primary completion: Jun 30, 2012 Completion: Jun 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01568567, this PHASE1/PHASE2 trial focuses on Safety and remains completed. Sponsored by BioGaia AB, it has been updated 5 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BioGaia AB
Good Food Practice, Sweden

Data source: Good Food Practice, Sweden

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Uppsala, Sweden